Recombinant antibodies for cancer diagnosis and therapy

Bibliography

• MILSTEIN C: With the benefit of hindsight. Immunol Today (2000) 21:359–364.
   PubMedGoogle Scholar
• WISEMAN GA, LEIGH B, ERWIN WD et al.: Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer (2002) 94:1349–1357.
   PubMed Web of Science ®Google Scholar
• CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev Cancer (2001) 1:118–129.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review on antibody designs for enhancing cancer immunotherapy.
   Google Scholar
• HUDSON PJ, SOURIAU C: Engineered antibodies. Nat. Med. (2003) 9:129–134.
   PubMed Web of Science ®Google Scholar
• BORREBAECK CA, CARLSSON R: Human therapeutic antibodies. Curr: Opin. Pharmacol (2001) 1:404–408.
   PubMedGoogle Scholar
• YOKOTA T, MILENIC DE,WHITLOW M, SCHLOM J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. (1992) 52:3402–3408.
   PubMed Web of Science ®Google Scholar
• KIM DJ, CHUNG JH, RYU YS et al.: Production and characterisation of a recombinant scFv reactive with human gastrointestinal carcinomas. Br. J. Cancer (2002) 87:405–413.
   PubMed Web of Science ®Google Scholar
• BIRD RE, HARDMAN KD, JACOBSON JW et al.: Single-chain antigen-binding proteins. Science (1988) 242:423–426.
   PubMed Web of Science ®Google Scholar
• HENDERIKX P, COOLEN-VAN NEER N, JACOBS A et al.: A human immunoglobulin G1 antibody originating from an M vitro- selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized. Am. J. Pathol (2002) 160:1597–1608.
   PubMed Web of Science ®Google Scholar
• MARTARELLO L, MCCONATHY J, CAMP VM et al.: Synthesis of syn- and anti-l-amino-3- [18F] fluoromethyl-cyclobutane-l-carboxylic acid (FMACBC), potential PET ligands for tumor detection. J. Med. Chem. (2002) 45:2250–2259.
   PubMed Web of Science ®Google Scholar
• CASEY JL, NAPIER MP, KING DJ et al: Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical Phase I/II study. Br. J. Cancer (2002) 86:1401–1410.
   PubMed Web of Science ®Google Scholar
• KORTT AA, DOLEZAL 0, POWER BE, HUDSON PJ: Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. (2001) 18:95–108.
   PubMedGoogle Scholar
• GROULET A, DORVILLIUS M, PELEGRIN A, BARBET J, BATY D: Pharmacokinetic and tumor-seeking properties of recombinant and nonrecombinant anti-carcinoembryonic antigen antibody fragments. Int. Cancer (2002) 100:367–374.
   PubMed Web of Science ®Google Scholar
• GOEL A, BARANOWSKA- KORTYLEWICZ J, HINRICHS SH et al: 99mTc-labeled divalent and tetravalent CC49 single-chain Fv: novel imaging agents for rapid in vivo localization of human colon carcinoma. J. Nucl. Med. (2001) 42:1519–1527.
   PubMed Web of Science ®Google Scholar
• LEE YC, BOEHM MK, CHESTER KA, BEGENT RH, PERKINS SJ: Reversible dimer formation and stability of the anti-tumour single-chain Fv antibody MFE-23 by neutron scattering, analytical ultracentrifugation, and NMR and FT-IRspectroscopy.Biol. (2002)320:107–127.
   Google Scholar
• WU AM, TAN GJ, SHERMAN MA et al:Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng. (2001) 14:1025–1033.
   PubMedGoogle Scholar
• YAZAKI PJ, SHIVELY L, CLARK C et al.:Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications. I Immunol Methods (2001) 253:195–208.
   PubMed Web of Science ®Google Scholar
• ARNDT KM, MULLER KM, PLUCKTHUN A: Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain. J. Ma Biol. (2001) 312:221–228.
   Web of Science ®Google Scholar
• GURA T: Therapeutic antibodies: magic bullets hit the target. Nature (2002) 417:584–586.
   PubMed Web of Science ®Google Scholar
• IZUMI Y, XU L, DI TOMASO E, FUKUMURA D, JAIN RK: Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature (2002) 416:279–280.
   PubMed Web of Science ®Google Scholar
• CARDARELLI PM, QUINN M, BUCKMAN D et al.: Binding to CD20 by anti-Bl antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Ioannina Immunother.(2002) 51:15–24.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG DM: Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. (2002) 43:693–713.
   PubMed Web of Science ®Google Scholar
• FLYNN AA, GREEN AJ, PEDLEY RB et al.: A model-based approach for the optimization of radioimmunotherapy through antibody design and radionuclide selection. Cancer (2002) 94:1249–1257.
   PubMed Web of Science ®Google Scholar
• LEWIS LD, BEELEN AP, COLE BF et al.: The pharmacokinetics of the bispecific antibody MDX-H210 when combined with interferon gamma-lb in a multiple-dose Phase I study in patients with advanced cancer. Cancer Chemother: Pharmacol (2002) 49:375–384.
   PubMed Web of Science ®Google Scholar
• RUNYON K, LEE K, ZUBEREK K, COLLINS M, LEONARD JP, DUNUSSI-JOANNOPOULOS K: The combination of chemotherapy and systemic immunotherapy with soluble B7-immunoglobulin G leads to cure of murine leukemia and lymphoma and demonstration of tumor-specific memory responses. Blood (2001) 97:2420–2426.
   PubMed Web of Science ®Google Scholar
• JUWEID ME: Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice. J. Nucl. Med. (2002) 43:1507–1529.
   PubMed Web of Science ®Google Scholar
• FLYNN AA, PEDLEY RB, GREEN AJ, BOXER GM, BODEN R, BEGENT RH: Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images. Cancer Biother. Radiopharm. (2001) 16:391–400.
   PubMed Web of Science ®Google Scholar
• WITZIG TE: Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother: Pharmacol (2001) 48 (Suppl. 1):591–595.
   Google Scholar
• KENNEL SJ, MIRZADEH S, ECKELMAN WC et al.: Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At. Radiat. Res. (2002) 157:633–641.
   PubMed Web of Science ®Google Scholar
• SGOUROS G, BALLANGRUD AM, JURCIC JG et al.: Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J. Nucl. Med. (1999) 40:1935–1946.
   PubMed Web of Science ®Google Scholar
• FLYNN AA, PEDLEY RB, GREEN AJ et al.: Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour. hat. J. Radial-. Biol. (2002) 78:407–415.
   PubMed Web of Science ®Google Scholar
• MATSUMURA H, °TSUJI E, KOBAYASHI S, OKAMOTO K, TOMA A, YAMAGISHI H: Potentialusefulness of 99mTc-labeled monoclonal antibody Al for immunoscintigraphy of human pancreatic carcinoma. Anticancer Res. (2001) 21:3433–3437.
   PubMed Web of Science ®Google Scholar
• MILENIC DE, GARMESTANI K, CHAPPELL LL et al: In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. Nucl. Med. Biol. (2002) 29:431–442.
   PubMed Web of Science ®Google Scholar
• NOVAK-HOFER I, SCHUBIGER PA: Copper-67 as a therapeutic nuclide for radioimmunotherapy. Ear: j Nucl. Med. Ma Imaging (2002) 29:821–830.
   Google Scholar
• LI L, OLAFSEN T, ANDERSON AL, WU A, RAUBITSCHEK AA,SHIVELY JE: Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diabody. Bioconjug. Chem. (2002) 13:985–995.
   Google Scholar
• WILLIAMS LE, WU AM, YAZAKI PJ et al.: Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother. Radiopharm. (2001) 16:25–35.
   PubMed Web of Science ®Google Scholar
• KIM MK, JEONG HJ, KAO CH et al: Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications. Nucl. Med. Biol. (2002) 29:139–146.
   PubMed Web of Science ®Google Scholar
• GRANA C, CHINOL M, ROBERTSON C et al.: Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. Cancer(2002) 86:207–212.
   Web of Science ®Google Scholar
• SCHUHMACHERJ, KLIVENYI G, KAUL S et al.: Pretargeting of human mammary carcinoma xenografts with bispecific anti-MUC 1 /anti- Ga chelate antibodies and immunoscintigraphy withPET. Nucl. Med. Biol. (2001) 28:821–828.
   PubMed Web of Science ®Google Scholar
• YAO Z, ZHANG M, AXWORTHY DB et al.: Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled1,4,7,10-tetraazacyclododecane-N,N',N',N"-tetraacetic acid (DOTA)-biotin. Cancer Res. (2002) 62:5755–5760.
   PubMed Web of Science ®Google Scholar
• KRIANGKUM J, XU B, NAGATA LP, FULTON RE, SURESH MR: Bispecificand bifunctional single chain recombinant antibodies. Biomol. Eng. (2001) 18:31–40.
   PubMedGoogle Scholar
• DMITRIEV DA, MASSINO YS, SEGAL OL et al: Analysis of the binding of bispecific monoclonal antibodies with immobilized antigens (human IgG and horseradish percoddase) using a resonant mirror biosensor. Immunol. Methods(2002) 261:103–118.
   PubMed Web of Science ®Google Scholar
• DENARDO DG, XIONG CY, SHI XB, DENARDO GL, DENARDO SJ: Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother. Radiopharm. (2001) 16:525–535.
   PubMed Web of Science ®Google Scholar
• LU D, JIMENEZ X, ZHANG H, BOHLEN P, WITTE L, ZHU Z: Fab-scEv fusion protein: an efficient approach to production of bispecific antibody fragments. I Immunol Methods(2002) 267:213–226.
   PubMed Web of Science ®Google Scholar
• HILLAIRET DE BOISFERON M, RAGUIN 0, THIERCELIN C et al: Improved tumor selectivity of radiolabeledpeptides by receptor and antigen dual targeting in the neurotensin receptor model.Bioconjug. Chem. (2002) 13:654–662.
   Google Scholar
• XIAO Z, MCQUARRIE SA, SURESH MR, MERCER JR, GUPTA S, MILLER GG: A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro. Biotechnol(2002) 94:171-184.a
   Google Scholar
• XIONG D, XU Y, LIU H et al.: Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody. Cancer Lett. (2002) 177:29–39.
   PubMed Web of Science ®Google Scholar
• TAKEMURA S, KUDO T, ASANO R et al.: A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunol. Immunother. (2002) 51:33–44.
   PubMed Web of Science ®Google Scholar
• WUEST T, MOOSMAYER D, PFIZENMAIER K: Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein.' Biotechnol. (2001) 92:159–168.
   Google Scholar
• LU D, JIMENEZ X, ZHANG H et al.: Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res.(2001) 61:7002–7008.
   PubMed Web of Science ®Google Scholar
• •A novel and efficient bispecific antibody strategy, including designs for inhibition of angiogenesis via receptor blockade.
   Google Scholar
• BALAIAN L, BALL ED: Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. Leak. Res. (2001) 25:1115–1125.
   PubMed Web of Science ®Google Scholar
• RUF P, LINDHOFER H: Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood (2001) 98:2526–2534.
   PubMed Web of Science ®Google Scholar
• •This article demonstrates the importance of the Fc region for immunotherapy.
   Google Scholar
• KIPRIYANOV SM, COCHLOVIUS B, SCHAFER HJ et al.: Synergistic antitumor effect of bispecific CD19 x CD3 and CD19x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. .1. Immunol.(2002) 169:137–144.
   Google Scholar
• ZEIDLER R, MAYER A, GIRES 0 et al.: TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res. (2001) 21:3499–3503.
   Google Scholar
• KODAMA H, SUZUKI M, KATAYOSE Y et al: Specific and effective targeting cancer immunotherapy with a combination of three bispecific antibodies. Immunol. Lett.(2002) 81:99–106.
   PubMed Web of Science ®Google Scholar
• VAN BEUSECHEM VW, GRILL J, MASTENBROEK DC et al.: Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors withnative tropism abolished.Virol. (2002)76:2753–2762.
   Web of Science ®Google Scholar
• MA Z, MI Z, WILSON A et al: Redirecting adenovirus to pulmonary endothelium by cationic liposomes. Gene Ther. (2002) 9:176–182.
   PubMed Web of Science ®Google Scholar
• EZZELL C: Magic bullets fly again. Sci. Am. (2001) 285:34–41.
   Google Scholar
• GARNETT MC: Targeted drug conjugates: principles and progress. Adv. Drug Deliv. Rev (2001) 53:171–216.
   PubMed Web of Science ®Google Scholar
• ROSS S, SPENCER SD, HOLCOMB I et al: Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res.(2002) 62:2546–2553.
   PubMed Web of Science ®Google Scholar
• BRINKMANN U, KEPPLER-HAFKEMEYER A, HAFKEMEYER P:Recombinant immunotoxins for cancer therapy. Expert Opin. Biol. The]:(2001) 1:693–702.
   PubMed Web of Science ®Google Scholar
• KOUSPAROU CA, EPENETOS AA, DEONARAIN MP: Antibody-guided enzyme therapy of cancer producing cyanide results in necrosis of targeted cells. Int. J. Cancer (200 2) 99:138–148.
   Google Scholar
• KHARE PD, LIAO S, HIROSE Y et al: Tumor growth suppression by a retroviral vector displaying scEv antibody to CEA and carrying the iNOS gene. Anticancer Res. (2002) 22:2443–2446.
   PubMed Web of Science ®Google Scholar
• TANG Y, LI Y, QIAN G: Tumor cell-specific gene transfer with retroviral vectors displaying single-chain antibody. ChM. Med. J. (Engl.) (2002) 115:1064–1069.
   PubMed Web of Science ®Google Scholar
• JIN N, CHEN W, BLAZAR BR, RAMAKRISHNAN S, VALLERA DA: Gene therapy of murine solid tumors with T cells transduced with a retroviral vascular endothelial growth factor-immunotoxin target gene. Hum. Gene Ther. (2002) 13:497–508.
   PubMed Web of Science ®Google Scholar
• HUSTON JS, GEORGE AJ: Engineered antibodies take center stage. Hum. Antibodies (2001) 10:127–142.
   PubMedGoogle Scholar
• MODI S, SEIDMAN AD: An update on epidermal growth factor receptor inhibitors. Curr: Oncol. Rep. (2002) 4:47–55.
   PubMedGoogle Scholar
• HARRINGTON KJ, MUBASHAR M, PETERS AM: Polyethylene glycol in the design of tumor-targetting radiolabelled macromolecules - lessons from liposomes and monoclonal antibodies. Q. J. Nucl. Med. (2002) 46:171–180.
   PubMedGoogle Scholar
• NAGATA S, ONDA M, NUMATA Yet at Novel anti-CD30 recombinant immunotwdns containing disulfide-stabilized Fv fragments. Clin. Cancer Res. (2002) 8:2345–2355.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ: Toxin-labeled monoclonal antibodies. Carr. Pharm. Biotechnol. (2001) 2:313–325.
   PubMedGoogle Scholar
• KREITMAN RJ: Chimeric fusion proteins-Pseudomonas exotwdn-based. Curt: Opin. Investig. Drugs (2001) 2:1282–1293.
   PubMedGoogle Scholar
• FRANKEL AE: Increased sophistication ofimmunotwdns. Clin. Cancer Res. (2002) 8:942–944.
   PubMedGoogle Scholar
• NIV R, ASSARAF YG, SEGAL D, PIRAK E, REITER Y: Targeting multidrug resistant tumor cells with a recombinant single- chain FV fragment directed to P-glycoprotein. Int. J. Cancer (2001) 94:864–872.
   PubMed Web of Science ®Google Scholar
• PEIPP M, KUPERS H, SAUL D et al.: Arecombinant CD7-specific single-chain immunotwdn is a potent inducer ofapoptosis in acute leukemic T cells.Cancer Res. (2002) 62:2848–2855.
   PubMed Web of Science ®Google Scholar
• KODAMA H, SUZUKI M, KATAYOSE Y et al.: Mutated SEA-D227A-conjugated antibodies greatly enhance antitumor activity against MUC1-expressing bile duct carcinoma. Cancer Immunol. Immunother. (2001) 50:539–548.
   PubMed Web of Science ®Google Scholar
• TUR MK, SASSE S, STOCKER M et al: An anti-GD2 single chain Fv selected by phage display and fused to Pseudomonas exotwdn A develops specific cytotoxic activity against neuroblastoma derived cell lines. Int. J. Mol. Med. (2001) 8:579–584.
   PubMed Web of Science ®Google Scholar
• UENO A, ARAKAWA F, ABE H et al: T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scEv antibody. Anticancer Res. (2002) 22:769–776.
   PubMed Web of Science ®Google Scholar
• NG PP, DELA CRUZ JS, SOROUR DN et al.: An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells. Proc. Nat. Acad. Sci. USA (2002) 99:10706–10711.
   PubMed Web of Science ®Google Scholar
• •An excellent demonstration of the potency of antibody-avidin fusions to induce apoptosis.
   Google Scholar
• HUHN M, SASSE S, TUR MK et al:Human angiogenin fused to human CD30 ligand (Ang-CD3OL) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res. (2001) 61:8737–8742.
   PubMed Web of Science ®Google Scholar
• GRUEL N, FRIDMAN WH, TEILLAUD JL: Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-FcgammaR scEv on cancer cell surface. Gene The]: (2001) 8:1721–1728.
   Google Scholar
• •An innovative strategy fusing an scEv to a receptor transmembrane domain, leading to induction of phagocytosis. A promising new approach.
   Google Scholar
• SHI N, BOADO RJ, PARDRIDGE WM: Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm. Res.(2001) 18:1091–1095.
   PubMed Web of Science ®Google Scholar
• WU D, SONG BW, VINTERS HV, PARDRIDGE WM: Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J. Drug Target. (2002) 10:239–245.
   PubMed Web of Science ®Google Scholar
• SHABAT D, LODE HN, PERTL U et al.:In vivo activity in a catalytic antibody-prodrug system: antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proc. Nat. Acad. Sci. USA (2001) 98:7528–7533.
   PubMed Web of Science ®Google Scholar
• WUEST T, GERLACH E, BANERJEE D, GERSPACH J, MOOSMAYER D, PFIZENMAIER K: TNF-selectokine: a novel prodrug generated for tumor targeting and site- specific activation of tumor necrosis factor. Oncogene (2002) 21:4257–4265.
   PubMed Web of Science ®Google Scholar
• SUZAWA T, NAGAMURA S, SAITO H et al.: Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. Control Release (2002) 79:229–242.
   PubMed Web of Science ®Google Scholar
• METELITSA LS, GILLIES SD, SUPER M, SHIMADA H, REYNOLDS CP, SEE GER RC: Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD 11 b/CD 18) for enhanced effector cell adhesion and azurophil granule exocytosis. Blood (2002) 99:4166–4173.
   PubMed Web of Science ®Google Scholar
• RUEHLMANN JM, XIANG R, NIETHAMMER AG et al.: MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res. (2001) 61:8498–8503.
   PubMed Web of Science ®Google Scholar
• STRUBE RW, CHEN SY: Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies. I Immunol. Methods (2002) 263:149–167.
   PubMed Web of Science ®Google Scholar
• VISINTIN M, SETTANNI G,MARITAN A, GRAZIOSI S, MARKS JD, CATTANEO A: The intracellular antibody capture technology (TACT): towards a consensus sequence for intracellular antibodies. J. Ma Biol. (2002) 317:73–83.
   Web of Science ®Google Scholar
• LUNDE E, WESTERN KH, RASMUSSEN IB, SANDLIE I,\BOGEN B: Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. Immunol. (2002) 168:2154–2162.
   Web of Science ®Google Scholar
• WIRTH S, BILLE F, KOENIG S et al.: Testing mouse mammary tumor virus superantigen as adjuvant in cytotoxic T-lymphocyte responses against a melanomatumor antigen. Int. J Cancer(2002) 99:201–206.
   PubMed Web of Science ®Google Scholar
• ALVAREZ-VALLINA L: Genetic approaches for antigen-selective cell therapy. Carr. Gene The]: (2001) 1:385–397.
   PubMedGoogle Scholar
• HOMBACH A, HEUSER C, ABKEN H: The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Carr. Gene The]: (2002) 2:211–226.
   PubMedGoogle Scholar
• SONDEL PM, HANK JA: Antibody-directed, effector cell-mediated tumor destruction. HematoL Oncol Clin. N Am. (2001) 15:703–721.
   PubMed Web of Science ®Google Scholar
• HANSEN HP, MATTHEY B, BARTH S et al.: Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. Int. .1. Cancer (2002) 98:210–215.
   Google Scholar
• FUJIOKA Y, ARANO Y, ONO Metal: Renal metabolism of 3'-iodohippuryl N(epsilon)-maleoyl-L-lysine (HML)-conjugated Fab fragments. Bioconjug. Chem. (2001) 12:178–185.
   PubMed Web of Science ®Google Scholar
• AHONEN C, MANNING E, ERICKSON LD et al: The CD4O-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat. Immunol (2002) 3:451–456.
   PubMed Web of Science ®Google Scholar
• AMSTUTZ P, FORRER P, ZAHND C, PLUCKTHUN A: In vitro display technologies: novel developments and applications. Carr. Opin. Biotechnol (2001) 12:400–405.
   PubMed Web of Science ®Google Scholar
• HOOGENBOOM HR: Overview of antibody phage-display technology and its applications. Methods MM. Biol.(2002) 178:1–37.
   PubMedGoogle Scholar
• ••This article provides a thorough and up-to-date review of the applications, opportunities and limitations of phage display technology.
   Google Scholar
• SANZ L, KRISTENSEN P, BLANCO B et al.: Single-chain antibody-based gene therapy: inhibition of tumor growth by in situ production of phage-derived human antibody fragments blocking functionally active sites of cell-associated matrices. Gene The]: (2002) 9:1049–1053.
   PubMed Web of Science ®Google Scholar
• SBLATTERO D, LOU J, MARZARI R, BRADBURY A: In vivo recombination as a tool to generate molecular diversity in phage antibody libraries. J. Biotechnol (2001) 74:303–315.
   PubMedGoogle Scholar
• O'CONNELL D, BECERRIL B, ROY-BURMAN A, DAWS M, MARKS JD: Phage versus phagemid libraries for generation of human monoclonal antibodies. J. Ma Biol. (2002) 321:49–56.
   Web of Science ®Google Scholar
• CHAMES P, HOOGENBOOM HR, HENDERIKX P: Selection of antibodies against biotinylated antigens. Methods Ma Biol. (2002) 178:147–157.
   PubMedGoogle Scholar
• DENKBERG G, COHEN CJ, LEV A, CHAMES P, HOOGENBOOM HR, REITER Y: Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc. Nat. Acad. ScL USA (2002) 99:9421–9426.
   PubMed Web of Science ®Google Scholar
• SCHEFFER GL, REURS AW, JUTTEN B et al: Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein. Br. J. Cancer (2002) 86:954–962.
   PubMed Web of Science ®Google Scholar
• BROCKS B, GARIN-CHESA P, BEHRLE E et al: Species-crossreactive scEv against the tumor stroma marker 'fibroblast activation protein' selected by phage display from an immunized FAP-/- knock-out mouse. Ma Med. (2001) 7:461–469.
   PubMed Web of Science ®Google Scholar
• TSE E, LOBATO MN, FORSTER A, TANAKA T, CHUNG GT, RABBITTS TH: Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J. Ma Biol. (2002) 317:85–94.
   Web of Science ®Google Scholar
• DE WILDT RM, TOMLINSON IM, ONG JL, HOLLIGER P: Isolation of receptor-ligand pairs by capture of long-lived multivalent interaction complexes. Proc. Nat. Acad. ScL USA (2002) 99:8530–8535.
   PubMed Web of Science ®Google Scholar
• LIU B, HUANG L, SIHLBOM C, BURLINGAME A, MARKS JD: Towards proteome-wide production of monoclonal antibody by phage display. J. MM. Biol. (2002) 315:1063–1073.
   PubMed Web of Science ®Google Scholar
• AMSTUTZ P, PELLETIER JN, GUGGISBERG A et al.: ha vitro selection for catalytic activity with ribosome display. J. Am. Chem. Soc. (2002) 124:9396–9403.
   PubMed Web of Science ®Google Scholar
• VAN DIJK MA, VAN DE WINKEL JG: Human antibodies as next generation therapeutics. Carr. Opin. Chem. Biol. (2001) 5:368–374.
   PubMed Web of Science ®Google Scholar
• ZHOU JM, FUJITA S, WARASHINA M, BABA T, TAIRA K: A novel strategy by the action of ricin that connects phenotype and genotype without loss of the diversity of libraries. J. Am. Chem. Soc. (2002) 124:538–543.
   PubMed Web of Science ®Google Scholar
• LAMLA T, MAMMERI K, ERDMANN VA: The cell-free protein biosynthesis-applications and analysis of the system. Acta Biochim. Poi (2001) 48:453–465.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI F, EBIHARA T, MIE M et al.: Ribosome display for selection of active dihydrofolate reductase mutants using immobilized methotrexate on agarose beads. FEBS Lett. (2002) 514:106–110.
   PubMed Web of Science ®Google Scholar
• JERMUTUS L, KOLLY R, FOLDES-PAPP Z, HANES J, RIGLER R, PLUCKTHUN A: Ligand binding of a ribosome-displayed protein detected in solution at the single molecule level by fluorescence correlation spectroscopy. Ear. Biophys. J. (2002) 31:179–184.
   PubMed Web of Science ®Google Scholar
• WITTRUP KD: Protein engineering by cell-surface display. Carr. Opin. Biotechnol (2001) 12:395–399.
   PubMed Web of Science ®Google Scholar
• •An excellent review on cell surface expression.
   Google Scholar
• FELDHAUS MJ, SIEGEL RW, OPRESKO LK et al: Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Nat. Biotechnol (2003) 21:163–170.
   PubMed Web of Science ®Google Scholar
• CHANG Q, ZHONG Z, LEES A, PEKNA M, PIROFSKI L: Structure-function relationships for human antibodies to pneumococcal capsular polysaccharide from transgenic mice with human immunoglobulin Loci. Infect. Immun. (2002) 70:4977–4986.
   PubMed Web of Science ®Google Scholar
• KUROIWA Y, KASINATHAN P, CHOI YJ et al.: Cloned transchromosomic calves producing human immunoglobulin. Nat. Biotechnol (2002) 20:889–894.
   PubMed Web of Science ®Google Scholar
• ROBINSON WH, DIGENNARO C, HUEBER W et al.: Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat. Med. (2002) 8:295–301.
   PubMed Web of Science ®Google Scholar
• BLANK K, LINDNERP, DIEFENBACH B, PLUCKTHUN A: Self-immobilizing recombinant antibody fragments for immunoaffinity chromatography: generic, parallel, and scalable protein purification. Protein Expr. Purif (2002) 24:313–322.
   PubMed Web of Science ®Google Scholar
• KAUFMANN M, LINDNER P, HONEGGER A et al.: Crystal structure of the anti-His tag antibody 3D5 single-chain fragment complexed to its antigen. J. Ma Biol. (2002) 318:135–147.
   Web of Science ®Google Scholar
• MURRAY A, MISSAILIDIS S, PRICE MR: Epitope affinity chromatography and biophysical studies of monoclonal antibodies and recombinant antibody fragments. J. Chromatogr. Sci. (2002) 40:343–349.
   PubMed Web of Science ®Google Scholar
• BAYLY AM, KORTT AA, HUDSON PJ, POWER BE: Large-scale bacterial fermentation and isolation of scFv multimers using a heat-inducible bacterial expression vector. J. Immunol. Methods (2002) 262:217–227.
   PubMed Web of Science ®Google Scholar
• DE GRAAF M, VAN DER MEULEN-MUILEMAN IH, PINEDO HM, HAISMA HJ: Expression of scFvs and scFv fusion proteins in eukaryotic cells. Methods Mol. Biol. (2002) 178:379–387.
   PubMedGoogle Scholar
• VAQUERO C, SACK M, SCHUSTER F et al.: A carcinoembryonic antigen-specific diabody produced in tobacco. FASEB (2002) 16:408–410.
   PubMed Web of Science ®Google Scholar
• SWENNEN D, PAUL ME VERNIS L, BECKERICH JM, FOURNIER A, GAILLARDIN C: Secretion of active anti-Ras single-chain Fv antibody by the yeasts Yarrowia lipolytica and Kluyveromyces lards. Microbiology (2002) 148:41–50.
   PubMed Web of Science ®Google Scholar
• CHOO AB, DUNN RD, BROADY KW, RAISON RL: Soluble expression of a functional recombinant cytolytic immunotoxin in insect cells. Protein Expr. Puril (2002) 24:338–347.
   PubMed Web of Science ®Google Scholar
• ARNDT KM, MULLER KM, PLUCKTHUN A: Helix-stabilized Fv (hsFv) antibody fragments: substituting the constant domains of a Fab fragment for a heterodimeric coiled-coil domain. J. Mol. Biol. (2001) 312:221–228.
   PubMed Web of Science ®Google Scholar
• HONEGGER A, PLUCKTHUN A: The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J. Mol. Biol. (2001) 309:687–699.
   Google Scholar
• HOYER W, RAMM K, PLUCKTHUN A: A kinetic trap is an intrinsic feature in the folding pathway of single-chain Fv fragments. Biophys. Chem. (2002) 96:273–284.
   PubMed Web of Science ®Google Scholar
• SAPHIRE EO, STANFIELD RL, CRISPIN MD et al: Contrasting IgG structures reveal extreme asymmetry and\flexibility.Biol. (2002) 319:9–18.
   Google Scholar
• DESMYTER A, DECANNIERE K, MUYLDERMANS S, WYNS L: Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. j. Biol. Chem. (2001) 276:26285–26290.
   PubMed Web of Science ®Google Scholar
• EWERT S, CAMBILLAU C, CONRATH K, PLUCKTHUN A: Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry (2002) 41:3628–3636.
   PubMed Web of Science ®Google Scholar
• MURUGANANDAM A, TANHA J, NARANG S, STANIMIROVIC D: Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB (2002) 16:240–242.
   PubMed Web of Science ®Google Scholar
• VAN DEN BEUCKEN T, VAN NEER N, SABLON E et al.: Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. (2001) 310:591–601.
   Google Scholar
• MUYLDERMANS S: Single domain camel antibodies: current status. J. Biotechnol. (2001) 74:277–302.
   PubMed Web of Science ®Google Scholar
• IRVING RA, COIA G, ROBERTS A, NUTTALL SD, HUDSON PJ: Ribosome display and affinity maturation: from antibodies to single V- domains and steps towards cancer therapeutics. Immunol. Methods (2001) 248:31–45.
   PubMed Web of Science ®Google Scholar
• LADNER RC, LEY AC: Novel frameworks as a source of high-affinity ligands. Curt: Opin. Biotechnol. (2001) 12:406–410.
   PubMed Web of Science ®Google Scholar
• SKERRA A: Anticalins': a new class of engineered ligand-binding proteins with antibody-like properties. Biotechnol. (2001) 74:257–275.
   Google Scholar
• KURTZMAN AL, GOVINDARAJAN S, VAHLE K, JONES JT, HEINRICHS V, PATTEN PA: Advances in directed protein evolution by recursive genetic recombination: applications to therapeutic proteins. Can: Opin. Biotechnol.(2001) 12:361–370.
   PubMed Web of Science ®Google Scholar
• MARTINEAU P: Error-prone polymerase chain reaction for modification of scFvs. Methods Mol. Biol. (2002) 178:287–294.
   PubMedGoogle Scholar
• IRVING RA, COIA G, RAICEVIC A, HUDSON PJ: Use of Escherichia coil mutator cells to mature antibodies. Methods Mol. Biol. (2002) 178:295–302.
   PubMedGoogle Scholar
• LANTTO J, JIRHOLT P, BARRIOS Y, OHLIN M: Chain shuffling to modify properties of recombinantimmunoglobulins. Methods Mot. Biol.(2002) 178:303–316.
   PubMedGoogle Scholar
• CHAMES P, WILLEMSEN RA, ROJAS G et al.: TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J. Immunol. (2002) 169:1110–1118.
   PubMed Web of Science ®Google Scholar
• REITER Y: Recombinant immunotoxins in targeted cancer cell therapy. Adv. Cancer Res. (2001) 81:93–124.
   PubMed Web of Science ®Google Scholar
• SALVATORE G, BEERS R,MARGULIES I, KREITMAN RJ, PASTAN I: Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res. (2002) 8:995–1002.
   PubMed Web of Science ®Google Scholar
• JUNG S, SPINELLI S, SCHIMMELE B et al.: The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibodyV(H) domains.Biol. (2001)309:701–716.
   Google Scholar
• VEREL I, HEIDER KH, SIEGMUND M et al.: Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. hat. J. Cancer (2002) 99:396–402.
   PubMed Web of Science ®Google Scholar
• ADAMS GP, SCHIER R, MCCALL AM et al.: High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. (2001) 61:4750–4755.
   PubMed Web of Science ®Google Scholar
• •An important observation which suggests that high affinity can also be a limitation for tumour targeting and particularly for tumour penetration.
   Google Scholar
• http://www.fda.gov/cber/efoi/approve.htm US Food and Drug Administration product approval information.
   Google Scholar
• •This and the following websites are useful with regards to recombinant antibodies, scFv fragments and libraries.
   Google Scholar
• http://www.lymphoma.com/ For latest product releases and treatment strategies.
   Google Scholar
• http://www.leukemia-lymphoma.org For latest product releases and treatment strategies.
   Google Scholar
• http://www.path.cam.ac.uld- mrc7/ humanisation/antibodies.html List of humanised antibodies.
   Google Scholar
• http://www.mgen.uni-heidelberg.de/SD/ SDscFvSite.html Antibody structures.
   Google Scholar
• http://www.mrc-cpe.cam.ac.uk/vbase-ok.php?menu=901 Vbase; human antibody sequences.
   Google Scholar
• http://www.antibodyresource.com Antibody resource links.
   Google Scholar
• http://www.rubic.rdg.ac.uld— andrew/ bioinf.org/abs/index5.htmlSACS- summary of antibody crystal structures and related antibody resource links.
   Google Scholar
• http://www.morphosys.com HuCAL scFv library.
   Google Scholar
• http://www.cambridgeantibody.com CAT scFv library.
   Google Scholar
• http://www.dyax.com Dyax Fab library.
   Google Scholar
• http://www.bioinvent.com BioInvent Ab library.
   Google Scholar
• http://www.biosite.com Triage TM diagnostics platform.
   Google Scholar
• http://www.zyomyx.comProtein Profiling BiochipTM array platform.
   Google Scholar
• http://www.perkinelmer.com HydrogelTM immobilised antibody platform.
   Google Scholar